4 not yet recruiting. 4 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 4 | Not yet recruiting 4 |
| Phase 2 | 1 | Not yet recruiting 1 |
Follow Tolerability: new trials by email Literature Review of Tolerability trials Research Report on Tolerability
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A First-in-Human SAD and MAD Study in Healthy Participants to Evaluate Oral YR011 Tablet Kv1.3 potassium channel blocker (PA032, investigational oral small-molecule drug), Placebo - Safety, Tolerability | Phase 1 | Not yet recruiting | Hangzhou Yirui Pharmaceutical Technology Co., Ltd | 64 | 2027-04-01 | 2026-07-30 |
| A First-in-Human SAD and MAD Study in HV to Evaluate Oral YR011 Tablet Kv1.3 potassium channel blocker (PA032, investigational oral small-molecule drug), Placebo - Safety, Tolerability | Phase 1 | Not yet recruiting | Hangzhou Yirui Pharmaceutical Technology Co., Ltd | 64 | 2027-01-01 | 2026-10-16 |
| Phase 1/2 Clinical Study of HY07121 for Injection (Subcutaneous) in Patients With Advanced Solid Tumors Test Product HY07121 for Injection (Subcutaneous) - Safety, Tolerability | Phase 1 / Phase 2 | Not yet recruiting | Sichuan Huiyu Pharmaceutical Co., Ltd | 254 | 2026-09-08 | 2026-08-27 |
| Single Ascending Dose and Multiple Ascending Dose Study of AVR-48 AVR-48, Placebo - Safety Issues, Tolerability | Phase 1 | Not yet recruiting | AyuVis Research, Inc. | 48 | 2025-06-01 | 2025-04-06 |
Injections (1) · Injections, Subcutaneous (1)
Hangzhou Yirui Pharmaceutical Technology Co., Ltd (2) · AyuVis Research, Inc. (1) · Sichuan Huiyu Pharmaceutical Co., Ltd (1)
United States (1)